Abstract
Ceftizoxime was evaluated in the treatment of 18 patients (6 adults and 12 children) with bacterial meningitis. In seven patients Haemophilus influenzae was the causative agent, in three Neisseria meningitidis, in five Streptococcus pneumoniae, and in one each alpha-streptococcus and Escherichia coli; one case was culture negative. Ceftizoxime was administered intravenously in doses of 200 mg/kg per day. Clinical response was appropriate in all patients with a mean time of defervescence of 3.7 days, and sterile cerebrospinal fluid was obtained from all patients at 24 to 36 h after initiation of therapy. The mean concentration of ceftizoxime in 46 cerebrospinal fluid samples obtained during therapy was 8.53 micrograms/ml (range, less than 0.5 to 29.0 micrograms/ml). Ceftizoxime concentrations in cerebrospinal fluid samples were ten- to several hundredfold the bactericidal concentrations of the pathogens isolated from the cerebrospinal fluid. Ceftizoxime penetrates the meninges well during acute infection and appears to be an excellent candidate antibiotic in the treatment of bacterial meningitis.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barry A. L., Jones R. N., Thornsberry C., Fuchs P. C., Gerlach E. H., Sommers H. M. Ceftizoxime: collaborative multiphased in-vitro evaluation including tentative interpretive standards for disc susceptibility tests, beta-lactamase stability, and inhibition. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):25–44. doi: 10.1093/jac/10.suppl_c.25. [DOI] [PubMed] [Google Scholar]
- Cable D., Edralin G., Overturf G. D. Human cerebrospinal fluid pharmacokinetics and treatment of bacterial meningitis with ceftizoxime. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):121–127. doi: 10.1093/jac/10.suppl_c.121. [DOI] [PubMed] [Google Scholar]
- Cable D., Overturf G., Edralin G. Concentrations of cefoperazone in cerebrospinal fluid during bacterial meningitis. Antimicrob Agents Chemother. 1983 May;23(5):688–691. doi: 10.1128/aac.23.5.688. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Corrado M. L., Gombert M. E., Cherubin C. E. Designing appropriate therapy in the treatment of gram-negative bacillary meningitis. JAMA. 1982 Jul 2;248(1):71–74. [PubMed] [Google Scholar]
- Del Rio M., McCracken G. H., Jr, Nelson J. D., Chrane D., Shelton S. Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis. Antimicrob Agents Chemother. 1982 Oct;22(4):622–627. doi: 10.1128/aac.22.4.622. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Greenwood D., Pearson N., Eley A., O'Grady F. Comparative in vitro activities of cefotaxime and ceftizoxime (FK749): new cephalosporins with exceptional potency. Antimicrob Agents Chemother. 1980 Mar;17(3):397–401. doi: 10.1128/aac.17.3.397. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kaplan S. L., Mason E. O., Jr, Garcia H., Kvernland S. J., Loiselle E. M., Anderson D. C., Mintz A. A., Feigin R. D. Pharmacokinetics and cerebrospinal fluid penetration of moxalactam in children with bacterial meningitis. J Pediatr. 1981 Jan;98(1):152–157. doi: 10.1016/s0022-3476(81)80562-8. [DOI] [PubMed] [Google Scholar]
- Yabuuchi E., Ito T., Tanimura E., Yamamoto N., Ohyama A. In vitro antimicrobial activity of ceftizoxime against glucose-nonfermentative gram-negative rods. Antimicrob Agents Chemother. 1981 Jul;20(1):136–139. doi: 10.1128/aac.20.1.136. [DOI] [PMC free article] [PubMed] [Google Scholar]